BNP Paribas Upgrades Genmab to Outperform, Boosts PT
22 april, 14:31
22 april, 14:31
08:31 AM EDT, 04/22/2026 (MT Newswires) -- BNP Paribas on Wednesday upgraded Danish healthcare company Genmab (GMAB.CO) to outperform from neutral and increased its price target to 2,400 Danish kroner from 1,300 kroner.
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
22 april, 14:31
08:31 AM EDT, 04/22/2026 (MT Newswires) -- BNP Paribas on Wednesday upgraded Danish healthcare company Genmab (GMAB.CO) to outperform from neutral and increased its price target to 2,400 Danish kroner from 1,300 kroner.
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Rapporter
Analys
Rapporter
Analys
1 DAG %
Senast
OMX Stockholm 30
0,82%
(11:41)
Kinnevik
Idag, 10:49
Största VD-köpen i april
OMX Stockholm 30
1 DAG %
Senast
3 060,53